Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (SE:IMMNOV)
:IMMNOV
Earnings Data
Report Date
Feb 24, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.04Last Year’s EPS
0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reveals significant progress in Immunovia's commercial transition and positive initial market response to PancreaSure, alongside key milestones in reimbursement rate setting. However, uncertainties remain regarding coverage and revenue timelines.Company Guidance
Successful Transition to Commercial Stage
Immunovia transitioned from a development stage to a commercial stage company with the launch of the PancreaSure test for early detection of pancreatic cancer.
Positive Initial Market Response
Within the first month of launch, 10 leading pancreatic cancer centers implemented PancreaSure, demonstrating significant advocacy among key opinion leaders.
Medicare Reimbursement Rate Set
Medicare set the clinical lab fee schedule rate for PancreaSure at $897, reflecting the test's clinical and economic value.
AFFIRM Study Results
The AFFIRM study showed 88% sensitivity for Stage III and IV pancreatic cancers, 10 percentage points higher than earlier stages, and 98% specificity in healthy controls.
Cash Flow and Financial Position
Immunovia reported a cash burn reduction to SEK 5.4 million per month, below the guidance of SEK 8-10 million, and successfully raised just over SEK 100 million.
SE:IMMNOV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:IMMNOV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 26, 2025 | kr0.26 | kr0.28 | +7.81% |
Aug 28, 2025 | kr0.70 | kr0.51 | -26.47% |
May 14, 2025 | kr0.31 | kr0.30 | -5.73% |
Feb 25, 2025 | kr0.33 | kr0.31 | -4.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immunovia AB (SE:IMMNOV) report earnings?
Immunovia AB (SE:IMMNOV) is schdueled to report earning on Feb 24, 2026, Before Open (Confirmed).
What is Immunovia AB (SE:IMMNOV) earnings time?
Immunovia AB (SE:IMMNOV) earnings time is at Feb 24, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Immunovia AB stock?
The P/E ratio of Immunovia AB is N/A.
What is SE:IMMNOV EPS forecast?
SE:IMMNOV EPS forecast for the fiscal quarter 2025 (Q4) is -0.04.